Business
Cipla inks partnership with China’sQilu Pharma for cancer biosimilar
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
This story summarizes reporting from The Hindu. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.
Read full story on The Hindu →
India — The Hindu


